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Production of TNF- and IL-1 in infectious and autoimmune dis-
eases is associated with fever, fatigue, and sleep disturbances,
which are collectively referred to as sickness behavior syndrome. In
mice TNF- and IL-1 increase nonrapid eye movement sleep. Be-
cause clock genes regulate the circadian rhythm and thereby
locomotor activity and may alter sleep architecture we assessed
the inﬂuence of TNF- on the circadian timing system. TNF- is
shown here to suppress the expression of the PAR bZip clock-
controlled genes Dbp, Tef, and Hlf and of the period genes Per1,
Per2, and Per3 in ﬁbroblasts in vitro and in vivo in the liver of mice
infused with the cytokine. The effect of TNF- on clock genes is
shared by IL-1, but not by IFN-, and IL-6. Furthermore, TNF-
interferes with the expression of Dbp in the suprachiasmatic
nucleus and causes prolonged rest periods in the dark when mice
show spontaneous locomotor activity. Using clock reporter genes
TNF- is found here to inhibit CLOCK-BMAL1-induced activation of
E-box regulatory elements-dependent clock gene promoters. We
suggest that the increase of TNF- and IL-1, as seen in infectious
and autoimmune diseases, impairs clock gene functions and causes
fatigue.
behavior  circadian rhythms  cytokines  innate immunity
In microbial infections, host defense mechanisms activate theinnate and adaptive arms of the immune response. Microbial
recognition byToll-like receptors (TLR) expressed bymacrophages
and dendritic cells leads to the activation of signal transduction
pathways with induction of various genes including IL-1, TNF-,
IL-6, and IFN-/ (1–3). These cytokines mediate the acute-phase
response, which is a systemic generalized reaction characterized by
fever, fatigue, and weight loss, an increase in the number of
neutrophils, and the induction of synthesis of acute-phase proteins
in the liver with increased haptoglobin, antiproteases, complement
components, fibrinogen, ceruloplasmin, and ferritin in the blood
(4). An acute phase response with a dose-dependent state of
lethargy and severe fatigue has been described in cancer patients
treated with TNF- (5). A link between production of TNF- and
daytime fatigue has also been suggested in rheumatoid arthritis
(RA) and in the obstruction sleep apnea syndrome (OSAS).
Inhibition of TNF- by soluble TNF-receptor p75 improves dis-
abling fatigue in patients with RA (6). A TNF--308 (A-G)
single-nucleotide polymorphism and elevated TNF- serum levels
have been described in OSAS (7, 8). Moreover, neutralization of
TNF- reduces daytime sleepiness in sleep apneics (9). Direct
effects of TNF- on spontaneous sleep are also shown in animal
studies. i.v., i.p., or intracerebroventricular injections of TNF- or
IL-1 enhance nonrapid eye-movement (NREM) sleep (for reviews,
see refs. 10 and 11). This increase in NREM sleep is independent
of the fever-inducing capacity of these cytokines (12). Although
there is good evidence for TNF- and IL-1 as mediators of altered
sleep–wake behavior, the underlying mechanisms remain elusive.
The regulation of sleep depends on a circadian control and a
homeostatic drive (13, 14). The circadian influence is provided
by the suprachiasmatic nuclei (SCN) of the hypothalamus being
entrained by light stimuli to the environment. This self-
sustaining circadian pacemaker uses a molecular mechanism
similar to the one used in subsidiary oscillators present in any
type of cell in the organism. The molecular clockwork involves
the transcriptional repressor genes Per1, Per2, Cry1, and Cry2, as
well as the transcriptional activators Bmal1 and Clock. The
heterodimerized transcription factor BMAL1:CLOCK activates
Per and Cry gene transcription by binding to E-box mo-
tives in their promoters. PER and CRY proteins inhibit
BMAL1:CLOCK complexes, thereby inhibiting their own gene
expression. This feedback-loop mechanism generates circadian
oscillations of Per and Cry expression. The same positive and
negative regulatory components also govern the rhythmic ex-
pression of the nuclear orphan receptor Rev-Erb, which in turn
represses the transcription of Bmal1 through direct binding to a
REV-ERB response element in the Bmal1 promoter. Thereby,
REV-ERB interconnects the cyclic expression of positive- and
negative-loop members (for reviews, see refs. 15 and 16). The
targeted inactivation of Bmal1 showed that this gene is indis-
pensable for the maintenance of circadian functions (17). Clock-
deficient mice show robust circadian patterns of locomotor
activity with period lengths shortened by only 20 min; Dbp
mRNA rhythm, however, was severely blunted in both the SCN
and the liver (18). The deletion of the clock-controlled genes
(CCG) PAR bZip transcription factors Dbp, Tef, and Hlf only
moderately affects the circadian clock but leads to pronounced
disturbances of locomotor activity. In the present study, our
objective was to examine (i) whether and how TNF- influences
the circadian timing system and modulates the expression of
clock genes and CCGs, and (ii) whether TNF- affects locomo-
tor activity, rest time, and periodicity in mice.
Results
Suppressed Expression of Clock Genes in TNF--Treated Synchronized
Fibroblasts. To determine whether TNF- interferes with circa-
dian gene expression, we used NIH 3T3 fibroblast cultures
synchronized by a 2-h serum shock; this system elicits a well
described circadian expression of central clock genes and CCGs
for at least three cycles (19). We analyzed serum shocked
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fibroblasts challenged over time with or without TNF- (10
ng/ml). RNA was extracted every 4 h thereafter up to Zeitgeber
time (ZT) 36 and analyzed by using quantitative real-time
RT-PCR methods. Within the first 12 h, the course of the
examined clock gene expression was not altered by TNF-
treatment. However, around the peak (ZT 20–28), TNF-
strikingly suppressed the expression of the central clock genes
Per1, Per2, and Per3 and of the CCGs Dbp, Tef, and Hlf. Peak
expression of Rev-erb mRNA at ZT 20 was slightly increased,
whereas Bmal1 expression was not affected by TNF-. Clock
expression was slightly increased. For all genes, TNF- did not
affect the phases but rather attenuated the amplitude of expres-
sion (Fig. 1A). Therefore, we assessed the extent of clock gene
expression at their main peak at ZT 24. TNF- induced a
significant reduction of gene expression for Per1, Per2, Per3,Dbp,
Tef, and Hlf genes. Rev-Erb expression, as assessed at its peak
of expression at ZT 20, remained unchanged by TNF-, as did
Clock (Fig. 1B). We extended the time of observation over a
second circadian cycle and analyzed rhythmic expression up to
60 h. In this, emphasis was placed on Dbp expression, because its
amplitude was the most affected by TNF-. Rhythmicity and
period length ofDbp expression were not changed by TNF-, but
its amplitude was severely suppressed at both peaks (Fig. 1C). To
determine whether the TNF--mediated suppression is revers-
ible, we washed out TNF- after the first cycle (at ZT 24) and
analyzed the second peak at ZT 48. By washing out TNF-, the
second peak of expression of Per1 and Per2 was restored, and
Dbp expression increased compared with the control where
TNF- still led to reduced peak expression. The expression of
Clock was not affected when extending the time of TNF-
treatment to 48 h (Fig. 1D). Moreover, the suppression of Dbp,
Per1, and Per2 gene expression in synchronized NIH 3T3 fibro-
blasts is clearly dose-dependent, being most significantly af-
fected with concentrations 1 ng/ml TNF-. The expression of
Clock remained unchanged irrespective of the dose of TNF-
(Fig. 1E).
IL-1, but Neither IFN Nor IL-6, Shares with TNF- the Effect to
Down-Regulate Clock Genes. Besides TNF-, other cytokines are
produced by TLR-activated macrophages and dendritic cells that
have been implicated in the sickness behavior syndrome, namely
the proinflammatory cytokines IL-1, IL-6, and IFN- and type
I IFN cytokines IFN- and - (20). Therefore, we examined
whether the effect of TNF- on clock genes is a unique property
of TNF- or is shared by other cytokines. Besides TNF-, also
IL-1 suppressed the expression of both, Dbp and Per3 (Fig. 2).
The expression of Dbp, Per1, Per2, and Per3 was not inhibited by
treatment of synchronized fibroblasts with IL-6 and IFN-.
IFN- induced a significant, albeit minor, suppression of Dbp
expression.
TNF- Interferes with E-Box-Dependent Transcription of Clock Genes.
Circadian transcriptional activation of Per genes and of the PAR
bZip transcription factor genes Dbp, Tef, and Hlf is thought to
depend on the binding of the heterodimer BMAL1:CLOCK to
the canonical or noncanonical E-box, a basic helix–loop–helix
transcription factor-binding site ideally harboring the sequence
CACGTG (21). In our study, TNF- affected suppression only
of the transcription of those clock genes harboring an E-box
upstream of the transcription initiation site (Per genes and Dbp,
Tef, and Hlf ). No suppression was observed on Bmal1 and Clock
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Fig. 1. TNF- impairs expression of clock genes in synchronized NIH 3T3
ﬁbroblasts. (A) TNF- attenuates circadian Per1/2/3 and PAR bZIP family (Dbp,
Tef, and Hlf ) gene expression. After serum shock (ZT 0–2), cells were kept in
serum-free medium with TNF- (10 ng/ml; open circles) or without the cyto-
kine (ﬁlled circles) and analyzed every 4 hwith quantitative real-time RT-PCR.
Results are shown as x-fold variations to nonsynchronized ﬁbroblast cultures
at ZT 0; three independent experiments; mean values  SD. (B) Per and PAR
bZIP family genes are signiﬁcantly down-regulated at the 24-h peak (TNF-:
gray bars; controls: black bars), whereas Clock and RevErb are not affected.
Expression of Rev-Erb was assessed at its peak at ZT 20. Data show one
representativeexperimentdone in triplicate (mean SD)of fourexperiments.
(C) The amplitudeofDbp expression in serum-shockedNIH3T3ﬁbroblastswas
attenuated during 60 h in the presence of TNF- (open circles) comparedwith
controls (ﬁlled circles). (D) Withdrawal of TNF- after the ﬁrst peak at ZT 24
shows that the suppression ofDbp, Per1, and Per2 at the second peak at ZT 48
is reversible. After serum shock, cells were treated with TNF- for 24 h (gray
bars), or for 48 h with or without a withdrawal of TNF- after 24 h (white and
black bars, respectively). Gene expression was compared with mock-treated
cells at the respective ZT (100% expression). Data show one representative
experiment done in triplicates (mean  SD) of three experiments. (E) The
suppression of the expression of Dbp, Per1, and Per2 in synchronized ﬁbro-
blasts at ZT 24 is dose-dependent being signiﬁcant (P 0.005) at doses higher
than 1 ng/ml TNF-. Data show the mean  SD of three independent exper-
iments performed in triplicates. For BDE, we used the independent-sample t
test; *, P  0,05; **, P  0,005; ***, P  0.0005.
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Fig. 2. Cytokine effects on Dbp, Per1, Per2, and Per3 in NIH 3T3 ﬁbroblasts.
Conﬂuent cells were synchronized with 50% horse serum for 2 h (ZT 0–2).
After serum shock, cells were kept in serum-free medium with TNF- (10
ng/ml), IL-1 (10 ng/ml), IL-6 (10 ng/ml), IFN- (10 ng/ml), IFN- (20 ng/ml) or
without cytokines and analyzed at ZT 24 with quantitative real-time RT-PCR.
Results are shown as percent of expression to noncytokine-treated ﬁbroblast
cultures; one representative experiment of three;mean values of triplicates
SD; independent sample t test; *, P  0,05; **, P  0,005; ***, P  0.0005.
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expression, their transcription not being E-box-dependent. Thus,
TNF- may interfere with E-box-mediated transcriptional acti-
vation. To test this hypothesis, we performed transient transfec-
tions of NIH 3T3 cells with luciferase reporter genes under the
control of the native 3- or 1.7-kB promoter sequences of mouse
Per1 and Per3, respectively, and of the 1-kB promoter of Bmal1
(Fig. 3A). Consistent with the gene expression studies, Per1 and
Per3 promoter activity was suppressed after TNF- administra-
tion but not that of the Bmal1 promoter, which is devoid of E-box
elements (Fig. 3B). To specify the possible effect on E-boxes, we
performed assays using NIH 3T3 cells stably transfected with a
luciferase reporter plasmid consisting of three E-boxes within 2.0
kb of the 5 f lanking region of the mouse Per1 gene with their
immediate flanking sequence linked together and joined to the
thymidine kinase promoter (22) (Fig. 3A). Again, treatment with
TNF- reduced luciferase activity by 45%, corresponding to the
basal activity of the basic pGL3-TK vector without E-boxes (Fig.
3C). An E-box reporter construct of the Dbp gene (Dbp-E-
box857; Fig. 3A) that was cotransfected with plasmids expressing
CLOCK and BMAL1 proteins showed expression reduced by
67%, indicating that overexpressed CLOCK and BMAL1 are
still efficiently blocked. In contrast, with the mutated E-box
(ACCAGT instead of CACATG) reporter construct (Dbp-857
mut), the activity was significantly derepressed (Fig. 3D). We
suggest therefore that TNF- suppresses E-box-mediated tran-
scription of clock genes. Thus, selective down-regulation of clock
genes or CCGs is likely to depend on the presence of E-box
elements in the respective genes.
Reduction of Clock Genes and CCGs in TNF--Treated Mice. To assess
the effect of TNF- on the expression of clock genes in vivo,
C57BL/6 mice were constantly infused with TNF- (1.5 g/day
or 0.075 mg/kg per day) via an osmotic minipump inserted s.c. on
the back of the mice over a period of 7 days (see Materials and
Methods). The dose chosen is10-fold lower than the dose used
to induce a septic shock-like disease in rats (0.7 mg/kg, admin-
istered intravenously) (23). Histopathology revealed no evidence
for TNF--induced vascular damage, hemorrhages, or inflam-
mation in the liver, lung, and kidney based on morphological
criteria and on the expression of heme oxygenase (HO-1), a
marker for oxidative stress. Macrophages of mice infused with
TNF- showed signs of being activated in the liver and kidney
[supporting information (SI) Fig. 6]. We found TNF- serum
concentrations at 43 (10.9) pg/ml at day three in TNF--
treated mice compared with 10 (0.8) pg/ml in controls (SI Fig.
7). In mice with experimental septic shock the respective value
for TNF- exceeds 10 ng/ml (24). In controls, osmotic pumps
were filled with diluent (PBS, 0.1% BSA). Total RNA was
extracted from the liver of mice treated with TNF- or control;
expression of clock genes was tested at day three at ZT 11.5 and
ZT 15.5 (ZT 0 6 a.m. lights on, ZT 12 6 p.m. lights off), when
we encountered maximal inhibition of locomotion (Fig. 5A). As
shown for fibroblasts in vitro, TNF- also suppressed the ex-
pression of Dbp, Tef and Hlf, and Per3, but not of Bmal1 and
Clock (Fig. 4). Although Per1 and Per2were down-regulated, this
was not significant. However, at a later time point (ZT 15.5),
when Per2 normally reaches its peak of expression, significant
suppression of Per2 was observed (Fig. 4 Lower). In contrast to
the fibroblast data, we found that TNF- suppressed the expres-
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Fig. 3. TNF- suppresses E-box-mediated transcription of clock genes. (A)
Schematic representation of the luciferase reporter genes used. mPer1-luc
(3-kb promoter fragment) andmPer3-luc (1.7-kb promoter fragment) contain
promoter sequences upstreamof their genes in the pGL3basic vector. pBmal1-
luc is regulatedbya1-kbpromoter fragmentanda1-kb sequenceof the3UTR
from mBmal1 gene. E54-TK consists of the three E-boxes of the mouse Per1
gene and their immediate ﬂanking sequences in front of a TK promoter.
DBP-Ebox857-luc contains one of four E-boxes of the Dbp promoter regulat-
ing the activity of a SV40 promoter. (B) Native clock gene promoters bearing
an E-box are affected by TNF-. Percent luciferase expression of mPer1-luc,
mPer3-luc, and pBmal1-luc transfected NIH 3T3 cells after treatment with 10
ng/ml TNF- overnight compared with untreated controls (100% luciferase
expression) is shown. (C) E-boxes of mPer1 are affected by TNF- treatment.
TNF- signiﬁcantly reduces E54-TK-dependent luciferase expression but not
pGL3-TK lacking E-boxes and ﬂanking sequences as shown by raw data (RLU,
relative light units; Left) and percent inhibition (Right). (D) The E-box of Dbp
gene at position857 is repressedby TNF- evenwhenCLOCKandBMAL1 are
overexpressed. Cotransfection with CLOCK and BMAL1 leads to four to ﬁve
times higher relative luciferase activity of 857wt compared with the mutated
E-box vector (857mut) indicating that the interaction of CLOCK:BMAL1 with
the E-box is functional. Luciferase activity is efﬁciently suppressed by over-
night treatmentwithTNF-as shownby rawdata (Left) andpercent inhibition
(Right). TNF- leads to a higher repression in 857wt than in 857mut. For all
assays, mean SD of triplicates from one representative experiment of three;
independent sample t test.
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Fig. 4. Impaired expression of clock genes in livers of TNF--infused mice.
Animals were entrained to a LD cycle during 2 weeks, and their locomotor
activity was constantly monitored via a passive infrared sensor and a running
wheel. Mice were then implanted with osmotic minipumps delivering TNF-
(light gray bars) or saline as control (dark gray bars). On the third day after the
operation, mice were killed at ZT  11.5 or  15.5 (ZT  0, light on; ZT  12,
light off). Livers were extracted and gene expression assessed by real-time
PCR. (A) Per1/2/3, RevErb, and PAR bZip family genes, Dbp, Hlf, and Tef, are
down-regulatedat both timepoints, the suppressionof PARbZip family genes
is highly signiﬁcant. In contrast to ﬁbroblast data, RevErb is strongly down-
regulated. Results are shown as percentages relative to the mean of the
control group. One representative experiment of three is shown (n  6 per
group; Mann–Whitney test. *, P  0,05; **, P  0,005.)
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sion of Rev-Erb. TNF- induced reduction of expression of the
Per genes and of PAR bZip transcription factor genes is likely to
influence the expression of clock output genes. Among the genes
that are positively regulated by DBP is the liver-specific albumin
gene (25). The capacity of TNF- to interfere with Dbp mRNA
expression is congruent with the observation of a decrease in
albumin serum concentration by 41% in TNF--treated mice
compared with controls (SI Fig. 8). TNF- has already been
described as inhibiting albumin synthesis in liver cells, but the
mechanisms remain elusive (26). Taken collectively, these data
provide evidence that the suppressive role of TNF- on Dbp is
associated with impaired activation of their target gene. TNF-
-treated mice also show higher endogenous expressions of
IL-1 and TNF- in the liver [both genes are well known to be
induced by TNF- (28)]; the level of expression of these cyto-
kines correlates with each other (SI Fig. 9). Furthermore, the
increased expression of the cytokines in the liver is associated
with a decrease of the CCG Dbp, Hlf, and Tef; the extent of the
decrease of these PAR bZip transcription factors fits to the
TNF- expression in individual mice (SI Fig. 9).
TNF- Reduces Dbp Expression in the SCN in the Hypothalamic Region.
To verify whether the effect of TNF- is sustained across the
blood–brain barrier and reaches the SCN, the expression of Dbp
was quantified. As described above, mice were implanted with
minipumps releasing TNF- or diluent; mice were killed after 3
days at ZT 6, when peak expression ofDbpwas expected. A slight
(	15%) but statistically significant reduction of Dbp expression
(P  0.003) can be seen by in situ hybridization in the SCN of
TNF--treated mice (SI Fig. 10). To verify the time point of the
rhythm, we used Bmal1, which, at peak expression of Dbp, is not
detectable. Indeed, unlike Dbp mRNA-positive cells, Bmal1
transcripts were not identified by in situ hybridization at ZT 6.
TNF- Reduces Locomotor Activity and Promotes Increased Rest Time
in Mice. The function of TNF- to interfere with the transcription
of distinct clock genes or CCGs prompted us to evaluate whether
TNF- alters the circadian rhythm and/or the amount of loco-
motor activity in vivo. The timing and extent of locomotor
activity were assessed with infrared sensors as well as by mon-
itoring running-wheel activity in mice recorded under a 12-h
light/12-h dark (LD) schedule. The surgical procedure led to a
decrease in locomotor activity that lasted for 48 h (infrared; Fig.
5A Upper). However, beside the more pronounced impairment
of locomotor activity on days 1 and 2, TNF- led also to a severe
suppression of locomotor activity on day 3; on this day, control
mice had attained baseline levels of activity. When running-
wheel activity was assessed, an analogous picture emerged with
maximum inhibition at day 3 (Fig. 5 A Lower and B). At later
time points, especially on days 5 and 6, TNF- no longer exerted
any effect on locomotor activity. This is most likely due to a
failed release of TNF- from the pump, because starting at day
4, hemorrhagic necrosis developed at the site of the pump. This
local side effect was noticed when pumps were filled with TNF-
but not with control solution and has been described in areas of
s.c. injection of TNF- in mice (3 g for 5 days) (29). Our results
show that TNF- leads to a decrease in the total amount of
locomotor activity as measured by a running-wheel and infrared
sensors until day 4 (Fig. 5A). The activity in both groups was still
restricted to the dark period, and highest loss of activity in
TNF- treated animals can be observed during the second half
of the active period (Fig. 5B). Further, based on these observa-
tions, we chose day 3 to investigate the frequency and duration
of rest episodes during the LD period (SI Fig. 11A). During the
light period, no change was observed. But in the dark period,
when mice are usually active, a significant increase in rest
episodes lasting 6–60 min was detected. As a readout of the
endogenous circadian clock, we assessed locomotor activity in
constant darkness (‘‘free-running condition’’) after implantation
of the minipumps and calculated the period length (). We
observed no changes in the periodicity of  (SI Fig. 11B). Taken
together, mice treated continuously with TNF- show reduced
motor activity and more consolidated rest time but no change in
period length under free-running conditions. These findings are
consistent with experiments with fibroblasts showing that the
amplitude of the expression of clock genes and CCGs are
attenuated by TNF-, rather than their circadian rhythm itself.
Discussion
Whereas the molecular mechanisms provided by clock genes to
maintain the circadian rhythm are becoming increasingly clear,
the potential influences of the immune system on the molecular
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Fig. 5. TNF- reduces locomotor activity ofmice but does not alter their circadian rest-activity cycles in free running conditions. (A) Reduced locomotor activities
inmicewith constant TNF- infusions are detected fromdays 1–4. Boxplot showing the changes of locomotor activity for each day afterminipump implantation
(TNF-, 1.5 g/day, for 6 days) or saline as control, compared with the baseline (mean of 3 days immediately before the operation). The TNF--treated group
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clockwork remain to be explored. Here, we provide evidence
that TNF- interferes with the expression of clock genes, namely
the Per genes and the PAR bZip genes Dbp, Tef, and Hlf. TNF-
suppresses the expression of these genes in fibroblasts (and
attenuates their amplitudes) in vitro and in vivo in the liver of
mice infused with this cytokine. That the same genes (with the
exception of RevErb) are prone to TNF- stimulation in vitro
compared with in vivo speaks for a rather direct effect of TNF-,
although we cannot exclude other intermediates involved leading
to the same response. In situ hybridization shows that the s.c.
administration of TNF- also leads to reduction of Dbp expres-
sion in the central circadian pacemaker, the SCN. Thus, it is
tempting to speculate that TNF- is likely to reach the SCN via
the blood and to bind to TNF receptor (TNF-R) on neurons. At
least in the hippocampus, both TNF-RI and -RII are expressed
(30). In the present study E-box regulatory elements of clock
genes are found here to play a pivotal role in the effect of TNF-
to inhibit clock gene expression. First, only clock genes with
E-boxes in their promoter, the PAR bZip genesDbp, Tef, andHlf
and the Per genes, are affected by TNF-, whereas clock genes
devoid of E-boxes such as Clock and Bmal1 are not affected by
TNF-. Second, mutated E-boxes provide protection of TNF-
-induced suppression of clock reporter genes. E-boxes are
functionally important components of DNA promoters that
guide the expression of clock genes and thereby influence the
circadian rhythm, including the sleep–wake cycle. Rhythmic
binding of CLOCK and BMAL1 depends on E-boxes and is a
prerequisite for robust waves of gene expression characteristic of
circadian transcription (31, 32).
The effects of TNF- on clock gene expression also become
apparent when studying clock-dependent genes. Dbp has been
described to mediate transcription of the albumin gene in
hepatocytes (25). Albumin serum concentrations are found here
to be lowered by 41% in TNF--treated mice compared with
controls.
Recording of locomotor activity of TNF--treated mice shows
more rest episodes during spontaneous activity. In line with the
finding that TNF- does not alter circadian rhythm in cultured
fibroblasts but rather lowers the extent of expression of distinct
clock genes, TNF- did not influence period length of the
circadian rhythm under ‘‘free running’’ conditions. Of interest
for the findings presented here are data showing that the
deletion of the Dbp gene in mice results in only a slight reduction
of period length but in a striking impairment of spontaneous
locomotor activity and running-wheel activity (33, 34). Whereas
Tef and Hlf single-knockout mice show an increased period
length, the inactivation of all three genes, Dbp, Tef, and Hlf,
resulted in an unchanged circadian period length (27). Thus, a
normal period length may be due to opposite effects leading to
mutual neutralization of indirect clock gene dysfunction. Besides
lowering the expression of PAR bZip transcription factors,
TNF- impaired Per1, Per2, and Per3 mRNA. Target disruption
of these genes results in slightly (Per3	/	 mice) or more dra-
matically (Per1	/	 mice) shortened period lengths or eventually
gives rise to arrhythmic behavior (Per2	/	 mice). Taken collec-
tively, TNF- interferes with the expression of E-box-dependent
clock genes and leads to prolonged rest episodes during spon-
taneous activity of mice.
Sleep architecture in humans is affected by the endogenous
circadian pacemaker, which regulates the timing of the sleep–
wake cycle, presumably by circadian expression of clock genes
(13, 35). Enhanced NREM sleep has been shown in mice treated
with muramyl dipeptides, which activate TLR2 and TLR4 on
macrophages (36, 37). TNF-, as well as IL-1, is produced by
TLR2- and TLR4-activatedmacrophages and is well described to
enhance NREM sleep (11, 38, 39). In light of the overlapping
properties of TNF- and IL-1 on NREM sleep, it is interesting
that our studies show IL-1 to share with TNF- the inhibitory
effect on expression of the Dbp and Per3 genes in fibroblasts. As
recently outlined, the effects of IL-6 on sleep differs from IL-1
and TNF-, in that it may also act on systems involved in NREM
sleep but not in REM sleep, which is suppressed by TNF- and
IL-1 but not by IL-6 (40). In this context, it may be of relevance
that the expression of Dbp is found here not to be affected by
IL-6. Although the expression of Dbp and Per1 is also not
inhibited by IFN-, IFN- only slightly interfered with Dbp
expression. This is remarkable, because in mice, the daily
injection of IFN- or - has been reported to lower Per1, Per2,
Per3, and Clock after 6 days of treatment (41). The absence of
effects of IFN- and - on expression of the Per genes by
synchronized fibroblasts in vitro indicates that IFNs down-
regulate the Per and Clock genes by E-box-independent mech-
anisms or induce production of other clock gene-regulating
factors when mice are treated over a long time period with the
cytokines.
In infectious diseases, TNF- serves to successfully eliminate the
infectious agent. The function of TNF- to interfere with the
expression of clock genes, to impair locomotor activity, and to
enhance rest may provide the link between the activation of the
innate immunity and fatigue associated with infectious and auto-
immunediseases, such asmultiple sclerosis,RA, orCrohn’s disease.
In these disorders, both fatigue and elevated TNF- concentrations
have been described (6, 42, 43). It is still debated whether sleep
changes in infections are beneficial to the host defense. Rabbits
infected with E. coli, Staphylococcus aureus, or Candida albicans
showed an improved prognosis when their sleep duration was
prolonged (44). In this context, it is to be noted that Per2	/	 mice
are partially protected from LPS-induced shock (45). During the
TNF--induced ‘‘inflammatory clock gene response,’’ the expres-
sion ofPer1,Per2, andPer3 genes and of thePARbZip transcription
factors Dbp, Tef, and Hlf is down-regulated, the locomotor activity
reduced, and rest episodes prolonged. Although this pathway may
induce an adaptive state in infectious diseases, the ‘‘inflammatory
clock gene response’’ may, by inducing fatigue, diminish the quality
of life in autoimmune diseases. Our study will serve to lay an
important foundation for further exploration of the connection
between the TNF--induced ‘‘inflammatory clock gene response’’
and the TNF--triggered reduction of locomotor activity.
Materials and Methods
Cytokines. Recombinant murine (rm) TNF-, rm IL-1, and rm
IL-6 were purchased either from Sigma (St. Louis, MO) (in vitro
time course assays) or from Peprotech (London, U.K.) (in vivo
assays); rm IFN- from Immunotools (Friesoythe, Germany),
and rm IFN- from Roche (Rotkreuz, Switzerland).
Synchronization of Fibroblasts by Serum Shock. NIH 3T3 fibroblasts
were grown in DMEM (Gibco, Basel, Switzerland) supple-
mented with 10% FBS (PAA Laboratories, Pasching, Austria)
and Glutamax (Gibco). For serum shock, cells were grown to
confluency in 6-cm tissue culture dishes. At time t  0, the
medium was exchanged by 50% horse serum (Gibco) in DMEM/
Glutamax; after 2 h, the medium was replaced with serum-free
DMEM/Glutamax, with or without TNF-. At the indicated time
points, tissue culture dishes were washed once with Hanks;
solution, frozen on a layer of liquid nitrogen, and kept at 	70°C
until the extraction of whole-cell RNA.
Transfection and Luciferase Assays. Unsynchronized NIH 3T3 cells
were transfected with the following constructs by using Lipo-
fectamine Plus (Life Technologies, Basel, Switzerland) or Trans-
Fectin (Bio-Rad, Hercules, CA) according to the manufacturer’s
protocol: mPer1-luc (46), kindly provided by David Earnest
[Texas A&M, College Station, TX; E54-TK (22)], kindly pro-
vided by Sato Honma (Hokkaido University, Sapporo, Japan);
Bmal1-luc (19), DBP-Ebox-luc and mut Ebox, pCDNA3.1-Clock
5
and pCDNA3.1-Bmal1 (47), kindly provided by U. Schibler
(University of Geneva, Geneva, Switzerland); mPer3-luc (48),
kindly provided by P. Sassone-Corsi (IGBMC, Illkirch, France).
As an internal control for transfection efficiency, a GFP con-
struct (pMax-GFP; Amaxa, Cologne, Germany) was cotrans-
fected 1:10.
Twenty-four hours after transfection, the medium was replaced
with serum-free DMEM/glutamax with or without TNF- (10
ng/ml). After 15 h, cells were lysed by using Passive Lysis Buffer
(Promega, Wallisellen, Switzerland) and enzyme activity was mea-
sured by the Luciferase Assay System (Promega). Bioluminescence
was measured with a Luminometer (Berthold Technologies, Re-
gensdorf, Switzerland) and normalized to transfection efficiency or
protein concentration.
Animal Groups and Locomotor Activity Recording. Seven-week-old
C57BL/6 male mice (Harlan Breeding Laboratory, AD Horst,
The Netherlands) were housed in individual cages, equipped
with a running-wheel and a passive infrared sensor in a tem-
perature-controlled sound-proof light-tight room. Food and
water were available ad libitum. We allowed mice 10–15 days of
acclimatization to a LD cycle (light on at 0600, i.e., ZT 0; light
off at 1800, i.e., ZT 12). Mice were operated under deep
isoflurane anesthesia, and 30 g of Temgesic anesthetic (bu-
prenorphine; Essex Chemie, Lucerne, Switzerland) was applied.
TNF- (1.5g/day, diluted in 0.1%BSA/PBS) or 0.1%BSA/PBS
as a control was administered s.c. by using osmotic minipumps
(Model 1007D; Alzet, Cupertino, CA) implanted on the back, for
6 days. Locomotor activity was continuously measured via
running-wheel and infrared sensors based on 1-min episodes by
using the Chronobiology Kit software (Stanford Software Sys-
tems, Santa Cruz, CA), as described (49, 50). Rest episodes were
defined as 1-min units with activity  zero. The free-running
period of locomotion was calculated by periodogram analysis for
days 2–6 after minipump implantation, when the mice were kept
in constant darkness. In gene expression studies, livers were
extracted 3 days after minipump insertion at two different ZTs
known to approximately represent the peak of expression of Dbp
(ZT  11.5) or Per2 (ZT  15.5). Livers were frozen in TRIzol
(Invitrogen, Basel, Switzerland) for subsequent RNA extraction.
All experimental procedures were approved by the local com-
mittee of the veterinary office and in strict accordance with Swiss
regulations on animal welfare.
RNA Isolation and Gene Expression Analysis. The method for RNA
extraction, RT-PCR, and quantification of gene expression is
described in SI Text.
In Situ Hybridization. The method for in situ hybridization was
published (51) and is described in SI Text.
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Fig. 6. Photomicrographs of histological sections of liver, lung and kidney with (top row) and 
without (bottom row) TNF-D treatment: The liver shows an increase in HO-1 positive Kupffer 
cells. At high power magnification the cells appear also larger. No morphologically apparent 
liver cell damage is however detected. The lung shows unremarkable numbers of HO-1 
positive macrophages in the bronchial mucus layer. No increase in HO-1 positive alveolar 
macrophages is seen. At high power magnification (hematoxylin eosin staining) increased 
numbers of megakaryocytes (indicated by arrows) are seen trapped within the alveolar 
vascular bed. There is, however, no evidence of pulmonary edema or acute pulmonary 
damage. Sections of the kidney (hematoxylin eosin staining) are unremarkable. The scale bar 
represents from left to right 400 Pm, 50 Pm, 200 Pm, 50 Pm, and 100 Pm, respectively. 
Fig. 7. At day 3 (ZT 15.5) after minipump insertion, serum was collected and TNF-D was 
measured by ELISA. Data are given as the mean r SD of TNF-D serum concentrations 
measured in six animals per group. Independent samples t test, P = 0.001. 
Fig. 8. Decreased concentrations of albumin in serum of TNF-D-treated mice. Serum was 
collected at day three after minipump implantation at ZT 15.5 and albumin concentrations 
were measured as described in materials and methods. Data show the mean rSD of serum 
albumin concentrations in mice (six mice per group). 
Fig. 9. IL1E expression correlates to TNF-D expression, both being increased in TNF-D
treated animals (circles with different colors, each individual mouse representing one color) 
compared to animals infused with PBS (blue open circles) (day 3, at ZT 15.5; 6 mice per 
group). In contrary, Dbp, Hlf, and Tef are negatively correlated to the relative TNF-D
expression.
Fig. 10. TNF-D impairs expression of the clock output genes, Dbp in the SCN. (A and B) Dbp
and Bmal1 expression in the SCN at ZT 6 as determined by radioactive in situ hybridization. 
At the time point of peak expression of Dbp, when Bmal1 expression is lowest, TNF-D leads 
to a significant reduction by 15% of the Dbp mRNA. (means r SEM of six consecutive 
sections per mouse SCN; four mice; paired t test; * P = 0.003). 
Fig. 11. (A) Mice treated with TNF-D show increased long rest epochs in the dark phase. 
Analysis of rest epochs was performed at day 3 of TNF-D and control infused mice; the 
analysis being performed separately for the light and dark period. The data show the 
differences in numbers of 1-min episodes with activity = 0 compared to baseline (mean of the 
three days before minipump insertion). The occurrence of rest was arbitrarily subdivided in 
episodes for durations with rest = 0 activity counts: up to 1 min rest, between 2 and 5 min, 6 
and 60 min, and more than 60 min. (ANOVA for repeated measures, followed by 
independent-samples t test; * P d0,05). (B) TNF-D does not affect the period length measured 
in constant darkness. On day 1 after minipump insertion the lights were turned off and the 
mice were kept in constant darkness. The circadian period of locomotion and running-wheel 
activity was determined by periodogram analysis over the 5 days in constant darkness. 
Independent-sample t-tests were performed. TNF-D (1.5 Pg/day; light gray bars) or saline as 
control (dark gray bars). 
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SI Text
RNA Isolation and Gene Expression Analysis
Whole-cell RNA from cultured cells was extracted using the NucleoSpin-RNA II kit 
(Macherey-Nagel, Switzerland). RNA from mouse tissues was extracted by homogenization 
of the organ in TRIzol (Invitrogen) according to the manufacturer's instructions. 
Subsequently, RNA was reverse-transcribed using random hexamers (Promega, for the in
vitro assays; Roche, for the in vivo assays) and AMV reverse transcriptase (Promega, for the 
in vitro assays) or M-MuLV reverse transcriptase (Roche, for the in vivo assays). The cDNA 
equivalent to 50 ng of total RNA was PCR-amplified in an ABI PRISM 7700 detection 
system (PE-Applied Biosystems) using the TaqMan Universal PCR Master Mix (Applied 
Biosystems) and quantified as follows. Primers and probes for Taqman analysis were either 
purchased from Applied Biosystems or purchased from Microsynth, Balgach, Switzerland, as 
described in detail in SI Table 1. The relative levels of each RNA were calculated by the 2-
''CT method (CT standing for the cycle number at which the signal reaches the threshold of 
detection); 18s rRNA was used as a housekeeping gene. Each CT value used for these 
calculations is the mean of two duplicates of the same reaction. Relative RNA levels are 
expressed as x-fold variations compared to ZT = 0 (time course experiments) or as 
percentages of the average control groups (in the in vitro one-time-point experiments and in 
the in vivo experiments). 
In situ hybridization 
After infusion of mice with saline or TNF-D mice were killed at day three at ZT 6. Brains 
were embedded in paraffin and sectioned at 7-Pm-thickness and hybridized with 35S-rUTP 
labeled riboprobes as described (1). The Bmal1 probe corresponded to nucleotides 654-1290 
(accession no. AF015953) and the Dbp probe to nucleotides 2-951 (accession no. 
NM016974). Quantification was performed by densitometric analysis of autoradiograph films 
using the Molecular analyst program (Bio-Rad). Data from the SCN were normalized to the 
lateral hypothalamus next to the SCN. For each treatment three animals were used and six 
sections per SCN were analyzed. We assessed the relative mRNA abundance values by 
defining the highest value of each experiment in mock treated animals as 100%. 
ELISA
The concentration of albumin and TNF-D in the serum of mice implanted with osmotic 
minipumps was determined by ELISA (Mouse Albumin ELISA Quantitation Kit, Bethyl 
Laboratories, TX, and mouse TNF-D ELISA kit, KMC3012, Biosource). 
1. Deboer T, Tobler I (2000) J Comp Physiol A 186:969-973 
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